AWC
RXRX icon

Adamsbrown Wealth Consultants’s Recursion Pharmaceuticals RXRX Stock Holding History

Adamsbrown Wealth Consultants’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.6K Hold
10,510
– – 0.01% 172
2026
Q1 		$32.3K Buy
+10,510
New +$40.6K 0.01% 138

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Adamsbrown Wealth Consultants's RXRX Position: Q2 2026 in Review

Adamsbrown Wealth Consultants held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 10,510 shares worth $38.6K. The position accounts for 0.01% of the portfolio, ranked #172.

Adamsbrown Wealth Consultants first reported a position in RXRX in Q1 2026 and has held it in 2 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Adamsbrown Wealth Consultants held 10,510 shares of Recursion Pharmaceuticals worth $38.6K as of Q2 2026.
  • Adamsbrown Wealth Consultants left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up 0.01% of Adamsbrown Wealth Consultants's portfolio in Q2 2026, its #172 holding.
  • Adamsbrown Wealth Consultants first reported a position in Recursion Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Adamsbrown Wealth Consultants's 13F filing for Q2 2026, filed 9 Jul 2026.